NCT03292133 2025-06-10A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung CancerMassachusetts General HospitalPhase 2 Terminated11 enrolled 10 charts
NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)NovartisPhase 1 Completed283 enrolled